Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
  • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems

Definitions

• the present invention relates to novel compounds that are MALTl (mucosa- associated lymphoid tissue lymphoma translocation protein 1) inhibitors. These compounds may be useful for the treatment of a disease, syndrome, condition, or disorder, particularly a MALTl-related disease, syndrome, condition, or disorder, including but not limited to, cancer and immunological diseases.
• MALTl molecular ALTl
• the invention also relates to
• compositions comprising one or more of such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the treatment of cancer and autoimmunological diseases, syndromes, disorders, or conditions associated with MALTl inhibitors.
• MALTl (mucosa-associated lymphoid tissue lymphoma translocation 1) is a key mediator of the classical NFKB signaling pathway. MALTl is the only human paracaspase and transduces signals from the B cell receptor (BCR) and T cell receptor (TCR). MALTl is the active subunit of the CBM complex which is formed upon receptor activation.
• the CBM complex consists of multiple subunits of three proteins: CARD 11 (caspase recruitment domain family member 11), BCL10 (B-cell CLL/Lymphoma 10) and MALTl .
• MALTl affects NFKB signaling by two mechanisms: firstly, MALTl functions as a scaffolding protein and recruits NF K B signaling proteins such as TRAF6, TAB-TAKl or ⁇ - ⁇ / ⁇ ; and secondly, MALTl, as a cysteine protease, cleaves and thereby deactivates negative regulators of NF K B signaling, such as RelB, A20 or CYLD.
• NF K B signaling proteins such as TRAF6, TAB-TAKl or ⁇ - ⁇ / ⁇
• MALTl as a cysteine protease, cleaves and thereby deactivates negative regulators of NF K B signaling, such as RelB, A20 or CYLD.
• the ultimate endpoint of MALTl activity is the nuclear translocation of the FKB transcription factor complex and activation of FKB signaling (Jaworski et al., Cell Mol Life Science 2016. 73, 459-473).
• DLBCL Diffuse Large B cell Lymphoma of the Activated B Cell-like subtype
• DLBCL is the most common form of non-Hodgkin's lymphoma (NHL), accounting for approximately 25% of lymphoma cases while ABC-DLBCL comprises approximately 40% of DLBCL.
• NFKB pathway activation is driven by mutations of signaling components, such as CD79A/B, CARD11, MYD88 or A20, in ABC-DLBCL patients (Staudt, Cold Spring Harb Perspect Biol 2010, 2; Lim et al, Immunol Rev 2012, 246, 359-378).
• BTK inhibitors for example Ibrutinib
• Ibrutinib provides clinical proof-of- concept that inhibiting NFKB signaling in ABC-DLBCL is efficacious.
• MALTl is downstream of BTK in the NFKB signaling pathway and a MALTl inhibitor could target ABC-DLBCL patients not responding to Ibrutinib, mainly patients with CARD 11 mutations, as well as treat patients that acquired resistance to Ibrutinib.
• API2 -MALTl The chromosomal translocation creating the API2 -MALTl fusion oncoprotein is the most common mutation identified in MALT (mucosa-associated lymphoid tissue) lymphoma.
• API2 -MALTl is a potent activator of the NFKB pathway (Rosebeck et al.,
• API2 -MALTl mimics ligand-bound TNF receptor, promotes TRAF2-dependent ubiquitination of RIP 1 which acts as a scaffold for activating canonical NFKB signaling. Furthermore, API2 -MALTl has been shown to cleave and generate a stable, constitutively active fragment of NFKB-inducing kinase (NIK) thereby activating the non-canonical FKB pathway (Rosebeck et al., Science, 2011, 331, 468- 472).
• NIK NFKB-inducing kinase
• MALT1 has been shown to play a critical role in innate and adaptive immunity (Jaworski M, etal., Cell Mol Life Sci. 2016). MALTl protease inhibitor can attenuate disease onset and progression of mouse experimental allergic encephalomyelitis, a mouse model of multiple sclerosis (Mc Guire et al., J.
• MALTl protease dead knock-in mice show a break of tolerance while conventional MALTl KO mice do not.
• MALTl protease dead knock-in mice Given the difference between genetic mutation and pharmacological inhibition, a phenotype of MALTl protease dead knock-in mice might not resemble that of patients treated with MALTl protease inhibitors. A reduction of immunosuppressive T cells by MALTl protease inhibition may be beneficial to cancer patients by potentially increasing antitumor immunity.
• MALTl inhibitors of the present invention may provide a therapeutic benefit to patients suffering from cancer and/or immunological diseases.
• the present invention is directed to compounds of Formula (I)
• Ri is selected from the group consisting of
• naphthalen-l-yl optionally substituted with a fluoro or amino substituent
• R.2 is selected from the group consisting of Ci-4alkyl, 1-methoxy-ethyl,
• G2 is N or C(R 3 ); such that only one of Gi and G2 are N in any instance;
• R.3 is independently selected from the group consisting of trifluoromethyl, cyano, Ci-4alkyl, fluoro, chloro, bromo, methylcarbonyl, methylthio, methyl sulfinyl, and methanesulfonyl; or, when Gi is N, R3 is further selected from Ci-4alkoxycarbonyl;
• R 4 is selected from the group consisting of
• a heteroaryl selected from the group consisting of triazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, thiazolyl, tetrazolyl, oxadiazolyl, imidazolyl, 2-amino- pyrimidin-4-yl, 2H-[l,2,3]triazolo[4,5-c]pyridin-2-yl, 2H-[l,2,3]triazolo[4,5- b] pyridin-2-yl, 3H-[l,2,3]triazolo[4,5-b]pyridin-3-yl, lH-[l,2,3]triazolo[4,5- c] pyridin-l-yl, wherein the heteroaryl is optionally substituted with one or two substituents independently selected from oxo, Ci-4alkyl, carboxy, methoxycarbonyl, aminocarbonyl, hydroxymethyl, aminomethyl, (di)
• R.5 is independently selected from the group consisting of hydrogen, chloro, fluoro, bromo, methoxy, methylsulfonyl, cyano, Ci-4alkyl, ethynyl, morpholin-4-yl,
• R 4 and R5 may be taken together to form 8-chloro-4-methyl-3-oxo-3,4-dihydro- 2H-benzo[b] [ 1 ,4]oxazin-6-yl, 8-chloro-3 -oxo-3 ,4-dihydro-2H-benzo[£] [ 1 ,4]oxazin-6-yl, 2- methyl-l-oxo-l,2,3,4-tetrahydroisoquinolin-7-yl, 4-methyl-3-oxo-3,4-dihydro-2H- benzo[b] [
• R 6 is hydrogen, Ci-4alkyl, fluoro, 2-methoxy-ethoxy, chloro, cyano, or
• R7 is hydrogen or fluoro; provided that a compound of Formula (I) is other than
• Ri is isoquinolin-8-yl
• R 2 is trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is 2H-l,2,3-triazol-2-yl, G2 is N, and R5 is hydrogen;
• Ri is isoquinolin-8-yl
• R 2 is trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is hydrogen, G2 is N, and R5 is fluoro;
• the present invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising, consisting of and/or consisting essentially of a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, and/or a pharmaceutically acceptable diluent and a compound of Formula (I), or a pharmaceutically acceptable salt form thereof.
• Also provided are processes for making a pharmaceutical composition comprising, consisting of, and/or consisting essentially of admixing a compound of Formula (I), and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, and/or a pharmaceutically acceptable diluent.
• the present invention further provides methods for treating or ameliorating a disease, syndrome, condition, or disorder in a subject, including a mammal and/or human in which the disease, syndrome, or condition is affected by the inhibition of MALTl, including but not limited to, cancer and/or immunological diseases, using a compound of Formula (I).
• the present invention also is directed to the use of any of the compounds described herein in the preparation of a medicament wherein the medicament is prepared for treating a disease, syndrome, condition, or disorder that is affected by the inhibition of MALTl, such as cancer and/or immunological diseases.
• the present invention is also directed to the preparation of substituted pyrazole derivatives that act as an inhibitor of MALTl .
• Exemplifying the invention are methods of treating a disease, syndrome, condition, or disorder mediated by MALT1, selected from the group consisting of lymphomas, leukemias, carcinomas, and sarcomas, e.g.
• non-Hodgkin's lymphoma diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa- associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, chonic lymphocytic leukemia (CLL), lymphoblastic T cell leukemia, chonic myelogenous leukemia (CML), hairy-cell leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocyte leukemia, promyelocytic leukemia, erytholeukemia, brain (gliomas), glioblastomas, breast cancer, colorectal/colon cancer, prostate cancer, lung cancer including non
• rhabdomyosarcoma medulloblastoma, neuroblastoma, cervical cancer, renal cancer, urothelial cancer, vulval cancer, esophageal cancer, salivary gland cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, and GIST (gastrointestinal stromal tumor), comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof a therapeutically effective amount of any of the compounds or pharmaceutical compositions described in the present invention.
• GIST gastrointestinal stromal tumor
• the present invention is directed to a compound of Formula (I) for use in the treatment of a disease, syndrome, condition, or disorder affected by the inhibition of MALT 1, selected from the group consisting of lymphomas, leukemias, carcinomas, and sarcomas, e.g.
• non-Hodgkin's lymphoma diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, chonic lymphocytic leukemia (CLL), lymphoblastic T cell leukemia, chonic myelogenous leukemia (CML), hairy-cell leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocyte leukemia, promyelocytic leukemia, eiytholeukemia, brain (gliomas), glioblastomas, breast cancer, colorectal/colon cancer, prostate cancer, lung cancer
• the present invention is directed to a composition comprising a compound of Formula (I) for the treatment of a disease, syndrome, condition, or disorder affected by inhibition of MALT1, selected from the group consisting of lymphomas, leukemias, carcinomas, and sarcomas, e.g.
• non-Hodgkin's lymphoma diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, chonic lymphocytic leukemia (CLL), lymphoblastic T cell leukemia, chonic myelogenous leukemia (CML), hairy-cell leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocyte leukemia, promyelocytic leukemia, eiytholeukemia, brain (gliomas), glioblastomas, breast cancer, colorectal/colon cancer, prostate cancer, lung cancer
• rhabdomyosarcoma medulloblastoma, neuroblastoma, cervical cancer, renal cancer, urothelial cancer, vulval cancer, esophageal cancer, salivary gland cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, and GIST (gastrointestinal stromal tumor).
• the present invention is directed to a composition
• a composition comprising a compound of Formula (I) for the treatment of a disease, syndrome, condition, or disorder affected by inhibition of MALTl, selected from the group consisting of diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and mucosa-associated lymphoid tissue (MALT) lymphoma.
• DLBCL diffuse large B-cell lymphoma
• MCL mantle cell lymphoma
• FL follicular lymphoma
• MALT mucosa-associated lymphoid tissue lymphoma
• An embodiment of the present invention is directed to a composition comprising a compound of Formula (I) for the treatment of immunological diseases that are affected by the inhibition of MALTl, including but not limited to, autoimmune and inflammatory disorders, e.g. arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcerative colitis, pancreatits, Crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplact rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, dermatitis including atopic, dermatomyositis, psoriasis, Behcet's diseases, uveitis, myasthenia gravis, Grave's disease, Hashimoto thyroiditis, Sjoergen's syndrome, blistering disorders, antibody- mediated vasculitis syndromes
• the present invention is directed to a composition comprising a compound of Formula (I) for the treatment of a disease, syndrome, condition, or disorder affected by inhibition of MALTl, selected from the group consisting of rheumatoid arthritis (RA), psoritic arthritis (PsA), psorisis (Pso), ulcerative colitis (UC), Crohn's disease, systemic lupus erythematosus (SLE), asthma, and chronic obstructive pulmonary disease (COPD).
• RA rheumatoid arthritis
• PsA psoritic arthritis
• Pso psorisis
• Ulative colitis UC
• Crohn's disease systemic lupus erythematosus
• COPD chronic obstructive pulmonary disease
• Another embodiment of the present invention is directed to a pharmaceutical composition comprising a compound of Formula (I). DETAILED DESCRIPTION OF THE INVENTION
• alkyl refers to straight and branched carbon chains having 1 to 8 carbon atoms. Therefore, designated numbers of carbon atoms (e.g., Ci-s) refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger alkyl-containing substituent. In substituent groups with multiple alkyl groups such as, (Ci-6alkyl)2amino-, the Ci-6alkyl groups of the dialkylamino may be the same or different.
• alkoxy refers to an -O-alkyl group, wherein the term “alkyl” is as defined above.
• alkenyl and alkynyl refer to straight and branched carbon chains having 2 to 8 carbon atoms, wherein an alkenyl chain contains at least one double bond and an alkynyl chain contains at least one triple bond.
• cycloalkyl refers to saturated or partially saturated, monocyclic or polycyclic hydrocarbon rings of 3 to 14 carbon atoms. Examples of such rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl.
• heterocyclyl refers to a nonaromatic monocyclic or bicyclic ring system having 3 to 10 ring members that include at least 1 carbon atom and from 1 to 4 heteroatoms independently selected from N, O, and S. Included within the term heterocyclyl is a nonaromatic cyclic ring of 5 to 7 members in which 1 to 2 members are N, or a nonaromatic cyclic ring of 5 to 7 members in which 0, 1 or 2 members are N and up to 2 members are O or S and at least one member must be either N, O, or S; wherein, optionally, the ring contains 0 to 1 unsaturated bonds, and, optionally, when the ring is of 6 or 7 members, it contains up to 2 unsaturated bonds.
• the carbon atom ring members that form a heterocycle ring may be fully saturated or partially saturated.
• heterocyclyl also includes two 5 membered monocyclic heterocycloalkyl groups bridged to form a bicyclic ring. Such groups are not considered to be fully aromatic and are not referred to as heteroaryl groups.
• heterocycle is bicyclic, both rings of the heterocycle are non-aromatic and at least one of the rings contains a heteroatom ring member.
• heterocycle groups include, and are not limited to, pyrrolinyl (including 2H-pyrrole, 2-pyrrolinyl or 3 -pyrrolinyl), pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl. Unless otherwise noted, the heterocycle is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
• aryl refers to an unsaturated, aromatic monocyclic or bicyclic ring of 6 to 10 carbon members. Examples of aryl rings include phenyl and naphthalenyl.
• heteroaryl refers to an aromatic monocyclic or bicyclic aromatic ring system having 5 to 10 ring members and which contains carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O, and S. Included within the term heteroaryl are aromatic rings of 5 or 6 members wherein the ring consists of carbon atoms and has at least one heteroatom member. Suitable heteroatoms include nitrogen, oxygen, and sulfur. In the case of 5 membered rings, the heteroaryl ring preferably contains one member of nitrogen, oxygen or sulfur and, in addition, up to 3 additional nitrogens. In the case of 6 membered rings, the heteroaryl ring preferably contains from 1 to 3 nitrogen atoms.
• heteroaryl groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzothiadiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl and quinazolinyl. Unless otherwise noted, the heteroaryl is attached to its pendant group at any
• halogen refers to fluorine, chlorine, bromine and iodine atoms.
• alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including those limitations given above for "alkyl” and "aryl.”
• Designated numbers of carbon atoms e.g., Ci-C 6
• the designated number of carbon atoms includes all of the independent members included within a given range specified.
• Ci-6 alkyl would include methyl, ethyl, propyl, butyl, pentyl and hexyl individually as well as sub-combinations thereof (e.g., C1-2, C1-3, Ci-4, C1-5, C2-6, C3-6, C4-6, C5-6, C2-5, etc.).
• the label "R” at a stereocenter designates that the stereocenter is purely of the R- configuration as defined in the art; likewise, the label “S” means that the stereocenter is purely of the ⁇ -configuration.
• the labels " *R” or “ *S” at a stereocenter are used to designate that the stereocenter is of pure but unknown absolute configuration.
• the label “RS” refers to a stereocenter that exists as a mixture of the R- and ⁇ -configurations.
• a compound containing one stereocenter drawn without a stereo bond designation is a mixture of two enantiomers.
• a compound containing two stereocenters both drawn without stereo bond designations is a mixture of four diastereomers.
• a compound with two stereocenters both labeled "RS" and drawn with stereo bond designations is a mixture of two enantiomers with relative stereochemistry as drawn.
• a compound with two stereocenters both labeled " RS" and drawn with stereo bond designations is a mixture of two enantiomers with a single, but unknown, relative stereochemistry.
• Unlabeled stereocenters drawn without stereo bond designations are mixtures of the R- and ⁇ -configurations.
• the relative and absolute stereochemistry is as depicted.
• subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
• terapéuticaally effective amount refers to an amount of an active compound or pharmaceutical agent, including a compound of the present invention, which elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, including reduction or inhibition of an enzyme or a protein activity, or ameliorating symptioms, alleviating conditions, slowing or delaying disease progression, or preventing a disease.
• the term "therapeutically effective amount” refers to the amount of a compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviate, inhibit, prevent, and/ or ameliorate a condition, or a disorder or a disease (i) mediated by MALTl; or (ii) associated with MALTl activity; or (iii) characterized by activity (normal or abnormal) of MALTl; or (2) reduce or inhibit the activity of MALTl; or (3) reduce or inhibit the expression of MALTl; or (4) modify the protein levels of MALTl .
• composition refers to a product that includes the specified ingredients in therapeutically effective amounts, as well as any product that results, directly, or indirectly, from combinations of the specified ingredients in the specified amounts.
• MALTl -mediated refers to any disease, syndrome, condition, or disorder that might occur in the absence of MALTl but can occur in the presence of MALTl . Suitable examples of a disease, syndrome, condition, or disorder mediated by MALTl include, but are not limited to, lymphomas, leukemias, carcinomas, and sarcomas, e.g.
• non-Hodgkin's lymphoma diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, chonic lymphocytic leukemia (CLL), lymphoblastic T cell leukemia, chonic myelogenous leukemia (CML), hairy-cell leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erytholeukemia, brain (gliomas), glioblastomas, breast cancer, colorectal/colon cancer, prostate cancer, lung
• MALTl inhibitor refers to an agent that inhibits or reduces at least one condition, symptom, disorder, and/or disease of MALTl .
• the term "affect" or "affected” when referring to a disease, syndrome, condition or disorder that is affected by the inhibition of MALTl includes a reduction in the frequency and / or severity of one or more symptoms or manifestations of said disease, syndrome, condition or disorder; and / or includes the prevention of the development of one or more symptoms or manifestations of said disease, syndrome, condition or disorder or the development of the disease, condition, syndrome or disorder.
• the term “treat”, “treating”, or “treatment” of any disease, condition, syndrome or disorder refers, in one embodiment, to ameliorating the disease, condition, syndrome or disorder (i.e. slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
• "treat”, “treating”, or “treatment” refers to alleviating or ameliorating at lease one physical parameter including those which may not be discernible by the patient.
• “treat”, “treating”, or “treatment” refers to modulating the disease, condition, syndrome or disorder either physically (e.g. stabilization of a discernible symptom), physiologically, (e.g. stabilization of a physical parameter), or both.
• “treat”, “treating”, or “treatment” refers to preventing or delaying the onset or development or progression of the disease, condition, syndrome or disorder.
• the compounds of the instant invention are useful in methods for treating or ameliorating a disease, a syndrome, a condition or a disorder that is affected by the inhibition of MALTl .
• Such methods comprise, consist of and/or consist essentially of administering to a subject, including an animal, a mammal, and a human in need of such treatment, amelioration and / or prevention, a therapeutically effective amount of a compound of Formula (I), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
• One embodiment of the present invention is directed to a method of treating a MALTl - dependent or MALTl -mediated disease or condition in a subject in need thereof, including an animal, a mammal, and a human in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
• the MALTl -dependent or MALTl -mediated disease or condition is selected from cancers of hematopoietic origin or solid tumors such as chonic myelogenous leukemia, myeloid leukemia, non-Hodgkin lymphoma, and other B cell lymphomas.
• the compounds of Formula (I), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof are useful for treating or ameliorating diseases, syndromes, conditions, or disorders such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and mucosa-associated lymphoid tissue (MALT) lymphoma.
• DLBCL diffuse large B-cell lymphoma
• MCL mantle cell lymphoma
• FL follicular lymphoma
• MALT mucosa-associated lymphoid tissue lymphoma
• the compounds of Formula (I), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof are useful for treating or ameliorating diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and mucosa-associated lymphoid tissue (MALT) lymphoma, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof as herein defined.
• DLBCL diffuse large B-cell lymphoma
• MCL mantle cell lymphoma
• FL follicular lymphoma
• MALT mucosa-associated lymphoid tissue
• the compounds of Formula (I), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof are useful for treating or ameliorating an immunological disease, syndrome, disorder, or condition selected from the group consisting of rheumatoid arthritis (RA), psoritic arthritis (PsA), psorisis (Pso), ulcerative colitis (UC), Crohn's disease, systemic lupus erythematosus (SLE), asthma, and chronic obstructive pulmonary disease (COPD).
• RA rheumatoid arthritis
• PsA psoritic arthritis
• Pso psorisis
• UC ulcerative colitis
• Crohn's disease systemic lupus erythematosus
• COPD chronic obstructive pulmonary disease
• Embodiments of the present invention include a compound of Formula (I)
• naphthalen-l-yl optionally substituted with a fluoro or amino substituent; or a heteroaryl of nine to ten members containing one to four heteroatoms selected from the group consisting of O, N, and S; such that no more than one heteroatom is O or S; wherein said heteroaryl of ii) is optionally independently substituted with one or two substituents selected from deuterium, methyl, ethyl, propyl, isopropyl, trifluoromethyl, methoxymethyl, difluoromethyl, 1,1-difluoroethyl, hydroxymethyl, 1- hydroxyethyl, hydroxy, methoxy, fluoro, chloro, bromo, cyano, amino, methylamino, 4-oxotetrahydrofuran-2-yl, 5-oxopyrrolidin-2-yl, 1,4- dioxanyl, aminocarbonyl, methylaminocarbonyl, oxo, N
• naphthalen-l-yl optionally substituted with a fluoro or amino substituent
• naphthalen-l-yl optionally substituted with an amino or fluoro substituent; or a heteroaryl of nine to ten members containing one to four heteroatoms selected from the group consisting of O, N, and S; such that no more than one heteroatom is O or S; wherein said heteroaryl of ii) is optionally independently substituted with one or two substituents selected from hydroxymethyl, 1 -hydroxy ethyl, hydroxy, fluoro, cyano, amino, 3- hydroxyazetidinyl, or oxo;
• naphthalen-l-yl 4-amino-naphthalen-l-yl, 4-fluoronaphthalen-l-yl, or 5- fluoronaphthalen- 1 -yl;
• a heteroaryl selected from the group consisting of isoquinolin-l-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, quinolin-7-yl, cinnolin- 4-yl, imidazo[l,2-a]pyrazin-8-yl, phthalazin-l-yl, naphthyridin-5-yl, thieno[3,2-c]pyridin-4-yl, furo[3,2-c]pyridin-4-yl, furo[2,3-c]pyridin-7-yl, quinoxalin-5-yl, lH-indazolylfuro[3,2-b]pyridin-7-yl, pyrazolo[l,5- a]pyrazin-4-yl, quinolin-4-yl, quinolin-5-yl, l-aminoisoquinolin-4-yl, 1- oxo-l,2-dihydr
• a heteroaryl selected from the group consisting of thieno[3,2-c]pyridin-4-yl, isoquinolin-4-yl, 8-fluoroquinolin-4-yl, furo[3,2-c]pyridin-4-yl, quinolin-5- yl, furo[2,3-c]pyridin-7-yl, benzofuran-4-yl l,7-naphthyridin-5-yl, pyrrolo[ 1 ,2-a]pyrazin- 1 -yl, imidazo[ 1 ,2-a]pyridin-5-yl, 1 -aminocarbonyl- isoquinolin-4-yl, pyrrolo[l,2-a]pyrazin-l-yl, benzo[d]thiazol-4-yl, 8-fluoro- l-hydroxyisoquinolin-4-yl, thieno[3,2-d]pyrimidin-4-yl, 8- fluoroimidazo
• R 2 is independently selected from the group consisting of methyl, isopropyl, cyano, bromo, chloro, and trifluoromethyl;
• R 2 is independently selected from the group consisting of methyl, isopropyl, cyano, and trifluoromethyl;
• HH) R 2 is trifluoromethyl
• R 3 is independently selected from the group consisting of trifluoromethyl, cyano, methylcarbonyl, methylthio, methylsulfinyl, methanesulfonyl, and chloro; or, when Gi is N, R 3 is further selected from Ci-4alkoxycarbonyl; JJ) R 3 is independently selected from the group consisting of trifluoromethyl, cyano, and chloro;
• G 2 is N or C(R 3 ), wherein R 3 is chloro; LL) G 2
• R 4 is selected from the group consisting of
• a heteroaiyl selected from the group consisting of triazolyl, oxazolyl,
• heteroaiyl is optionally substituted with one or two substituents independently selected from the group consisting of Ci-4alkyl, carboxy, methoxycarbonyl, hydroxymethyl, aminocarbonyl, (dimethylamino)methyl, amino, methoxy methyl, trifluoromethyl, amino(C2-4alkyl)amino, and cyano; vii) l-methyl-piperidin-4-yloxy;
• R 4 is selected from the group consisting of
• a heteroaiyl selected from the group consisting of triazolyl, oxazolyl,
• heteroaiyl is optionally substituted with one or two substituents independently selected from the group consisting of methyl, carboxy, methoxycarbonyl, hydroxymethyl, aminocarbonyl, (dimethylamino)methyl, and amino, methoxymethyl;
• R.4 is selected from the group consisting of
• a heteroaryl independently selected from the group consisting of 2H-1,2,3- triazol-2-yl, 4-carboxy-2H- 1 ,2,3 -triazol-2-yl, 4-(hydroxymethyl)-2H- 1,2,3- triazol-2-yl, 4-methyl-2H-l,2,3-triazol-2-yl, oxazol-2-yl, 4-amino-2H-l,2,3 triazol-2-yl, 4-(hydroxymethyl)- IH-pyrazol- 1 -yl, 4-(hydroxymethyl)-2H- l,2,3-triazol-2-yl, 4-((dimethylamino)methyl)-2H-l,2,3-triazol-2-yl, 4- methoxycarbonyl-2H- 1 ,2,3 -triazol-2-yl, 4-aminocarbonyl-2H- 1 ,2,3 -triazol- 2-yl,l -methyl- lH-pyrazol-3-y
• R.4 is independently selected from the group consisting of 2H-l,2,3-triazol-2-yl, 4- carboxy-2H- 1 ,2,3 -triazol-2-yl, 4-(hydroxymethyl)-2H- 1 ,2,3 -triazol-2-yl, 4-methyl- 2H-l,2,3-triazol-2-yl, oxazol-2-yl, lH-imidazol-2-yl, 4-amino-2H-l,2,3-triazol-2- yl, 4-(hydroxymethyl)- IH-pyrazol- 1 -yl, 4-(hydroxymethyl)-2H- 1 ,2,3-triazol-2-yl, 4-((dimethylamino)methyl)-2H-l,2,3-triazol-2-yl, 4-methoxycarbonyl-2H-l,2,3- triazol-2-yl, 4-aminocarbonyl-2H-l,2,3-triazol-2-yl,l-methyl-
• R.5 is hydrogen, chloro, fluoro, bromo, cyano, methyl, ethyl, or trifluoromethyl; or, R 4 and Rs may be taken together to form 8-chloro-4-methyl-3-oxo-3,4-dihydro-2H- benzo[ ][l,4]oxazin-6-yl or 8-chloro-3-oxo-3,4-dihydro-2H-benzo[£][l,4]oxazin- 6-yl;
• R5 is hydrogen, chloro, bromo, cyano, or trifluoromethyl; or, R 4 and R5 may be taken together to form 8-chloro-4-methyl-3-oxo-3,4-dihydro-2H- benzo[ ][l,4]oxazin-6-yl or 8-chloro-3-oxo-3,4-dihydro-2H-benzo[£][l,4]oxazin- 6-yl;
• R5 is hydrogen, chloro, bromo, or cyano
• TT is hydrogen, chloro, or cyano
• UU is hydrogen or methyl
• VV is hydrogen; and any combination of embodiments AA) though VV) above, provided it is understood that combinations in which different embodiments of the same substituent would be combined are excluded; such that only one of Gi and G2 are N in any instance; and provided that a compound of Formula (I) is other than
• Ri is isoquinolin-8-yl
• R 2 is trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is 7H-l,2,3-triazol-l-yl, G2 is N, and R5 is hydrogen;
• Ri is isoquinolin-8-yl, R21S trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is hydrogen, G2 is N, and R5 is fluoro;
• Embodiments of the present invention include a compound of Formula (I)
• Ri is selected from the group consisting of
• naphthalen-l-yl 4-amino-naphthalen-l-yl, or 4-fluoronaphthalen-l-yl, 5- fluoronaphthalen- 1 -yl;
• R.2 is independently selected from the group consisting of methyl, isopropyl, cyano, bromo, chloro, and trifluoromethyl;
• G2 is N or C(R 3 ); such that only one of Gi and G2 is N in any instance;
• R 3 is independently selected from the group consisting of trifluoromethyl, cyano, methylcarbonyl, methylthio, methylsulfinyl, methanesulfonyl, and chloro; or, when Gi is N, R 3 is further selected from Ci-4alkoxycarbonyl;
• R 4 is independently selected from the group consisting of
• a heteroaryl selected from the group consisting of triazolyl, oxazolyl, pyrazolyl, thiazolyl, oxadiazolyl, imidazolyl, and pyrimidin-4-yl, wherein the heteroaryl is optionally substituted with one or two substituents independently selected from the group consisting of Ci-4alkyl, carboxy, methoxycarbonyl, hydroxymethyl, aminocarbonyl, (dimethylamino)methyl, amino, methoxymethyl, trifluoromethyl, amino(C2-4alkyl)amino, and cyano;
• R.5 is hydrogen, chloro, fluoro, bromo, cyano, methyl, ethyl, or trifluoromethyl; or, R 4 and Rs may be taken together to form 8-chloro-4-methyl-3-oxo-3,4-dihydro-2H- benzo[ ][l,4]oxazin-6-yl or 8-chloro-3-oxo-3,4-dihydro-2H-benzo[£][l,4]oxazin-6-yl;
• R 6 is hydrogen or methyl
• Ri is isoquinolin-8-yl
• R 2 is trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is 2H-l,2,3-triazol-2-yl, G2 is N, and R5 is hydrogen;
• Ri is isoquinolin-8-yl
• R 2 is trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is /H-imidazol-l-yl, G2 is N, and R5 is chloro;
• Ri is isoquinolin-8-yl, R21S trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is 7H-l,2,3-triazol-l-yl, G2 is N, and R5 is hydrogen;
• Ri is isoquinolin-8-yl, R21S trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is hydrogen, G2 is N, and R5 is fluoro;
• Embodiments of the present invention include a compound of Formula (I)
• Ri is selected from the group consisting of
• naphthalen-l-yl optionally substituted with a fluoro or amino substituent
• R2 is selected from the group consisting of methyl, isopropyl, cyano, and trifluoromethyl;
• G2 is N or C(R 3 ); such that only one of Gi and G2 is N in any instance;
• R 3 is independently selected from the group consisting of trifluoromethyl, cyano, and chloro;
• R 4 is independently selected from the group consisting of
• a heteroaryl selected from the group consisting of triazolyl, oxazolyl, pyrazolyl, thiazolyl, oxadiazolyl, and imidazolyl, wherein the heteroaryl is optionally substituted with one or two substituents independently selected from the group consisting of methyl, carboxy, methoxycarbonyl, hydroxymethyl, aminocarbonyl, (dimethylamino)methyl, and amino, methoxymethyl;
• R.5 is hydrogen, chloro, bromo, or cyano
• R.6 is hydrogen or methyl
• Rj is hydrogen; provided that a compound of Formula (I) is other than
• Ri is isoquinolin-8-yl, R21S trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is 2H-l,2,3-triazol-2-yl, G2 is N, and R5 is hydrogen;
• Ri is isoquinolin-8-yl
• R 2 is trifluoromethyl
• Gi is C(R 4 ) wherein R 4 is hydrogen, G2 is N, and R5 is fluoro;
• Embodiments of the present invention include a compound of Formula (I)
• Ri is selected from the group consisting of
• naphthalen-l-yl optionally substituted with a fluoro or amino substituent
• R2 is selected from the group consisting of methyl, isopropyl, cyano, and trifluoromethyl;
• G2 is N or C(R 3 ); such that only one of Gi and G2 is N in any instance;
• R 3 is independently selected from the group consisting of trifluoromethyl, cyano, and chloro;
• R 4 is selected from the group consisting of
• a heteroaryl selected from the group consisting of 2H-l,2,3-triazol-2-yl, 4-carboxy- 2H-l,2,3-triazol-2-yl, 4-(hydroxymethyl)-2H-l,2,3-triazol-2-yl, 4-methyl-2H-l,2,3- triazol-2-yl, oxazol-2-yl, 4-amino-2H-l,2,3-triazol-2-yl, 4-(hydroxymethyl)-lH- pyrazol-l-yl, 4-(hydroxymethyl)-2H-l,2,3-triazol-2-yl, 4- ((dimethylamino)methyl)-2H- 1 ,2,3 -triazol-2-yl, 4-methoxycarbonyl-2H- 1,2,3- triazol-2-yl, 4-aminocarbonyl-2H-l,2,3-triazol-2-yl,l-methyl-lH-pyrazol-3-yl, l,
• R5 is hydrogen, chloro, or cyano
• R 6 is hydrogen or methyl
• R7 1S hydrogen; enantiomer, diastereomer, or pharmaceutically acceptable salt form thereof.
• Embodiments of the present invention include a compound of Formula (I)
• Ri is independently selected from the group consisting of
• naphthalen-l-yl 4-amino-naphthalen-l-yl, 4-fluoronaphthalen-l-yl, or 5- fluoronaphthalen- 1 -yl;
• a heteroaryl selected from the group consisting of isoquinolin-l-yl, isoquinolin-4- yl, isoquinolin-5-yl, isoquinolin-8-yl, quinolin-7-yl, cinnolin-4-yl, imidazo[l,2- a]pyrazin-8-yl, phthalazin-l-yl, naphthyridin-5-yl, thieno[3,2-c]pyridin-4-yl, furo[3,2-c]pyridin-4-yl, furo[2,3-c]pyridin-7-yl, quinoxalin-5-yl, ⁇ H- indazolylfuro[3,2-b]pyridin-7-yl, pyrazolo[l,5-a]pyrazin-4-yl, quinolin-4-yl, quinolin-5-yl, l-aminoisoquinolin-4-yl, l-oxo-l
• R2 is trifluorom ethyl
• G2 is N or C(R 3 ); such that only one of Gi and G2 is N in any instance;
• R 3 is independently selected from the group consisting of trifluoromethyl, cyano, and chloro;
• R 4 is independently selected from the group consisting of 2H-l,2,3-triazol-2-yl, 4- carboxy-2H-l,2,3-triazol-2-yl, 4-(hydroxymethyl)-2H-l,2,3-triazol-2-yl, 4-methyl-2H- l,2,3-triazol-2-yl, oxazol-2-yl, lH-imidazol-2-yl, 4-amino-2H-l,2,3-triazol-2-yl, 4- (hydroxymethyl)- lH-pyrazol- 1 -yl, 4-(hydroxymethyl)-2H- 1 ,2,3 -triazol-2-yl, 4- ((dimethylamino)methyl)-2H- 1 ,2,3 -triazol-2-yl, 4-methoxycarbonyl-2H- 1 ,2,3 -triazol-2-yl, 4-aminocarbonyl-2H-l,2,3-triazol-2-yl,l-methyl-
• R5 is hydrogen, chloro, bromo, or cyano
• R 6 is hydrogen or methyl; R7 1S hydrogen; or an enantiomer, diastereomer, or pharmaceutically acceptable salt form thereof.
• Embodiments of the present invention include a compound of Formula (I)
• Ri is independently selected from the group consisting of
• napthalen-l-yl 4-amino-naphthalen-l-yl, 4-fluoronaphthalen-l-yl, or 5- fluoronaphthalen- 1 -yl;
• a heteroaryl selected from the group consisting of thieno[3,2-c]pyridin-4-yl, isoquinolin-4-yl, 8-fluoroquinolin-4-yl, furo[3,2-c]pyridin-4-yl, quinolin-5-yl, furo[2,3-c]pyridin-7-yl, benzofuran-4-yl l,7-naphthyridin-5-yl, pyrrolo[l,2- a]pyrazin- 1 -yl, imidazo[ 1 ,2-a]pyridin-5-yl, 1 -aminocarbonyl-isoquinolin-4-yl, pyrrolo[ 1 ,2-a]pyrazin- 1 -yl, benzo[d]thiazol-4-yl, 8-fluoro- 1 -hydroxyisoquinolin-4- yl, thieno[3,2-d]pyrimidin-4-yl, 8-fluoroimi
• R2 is trifluorom ethyl
• G2 is N or C(R 3 ); such that only one of Gi and G2 is N in any instance;
• R 3 is independently selected from the group consisting of trifluoromethyl, cyano, and chloro;
• R 4 is independently selected from the group consisting of 2H-l,2,3-triazol-2-yl, 4- carboxy-2H-l,2,3-triazol-2-yl, 4-(hydroxymethyl)-2H-l,2,3-triazol-2-yl, 4-methyl-2H- l,2,3-triazol-2-yl, oxazol-2-yl, lH-imidazol-2-yl, 4-amino-2H-l,2,3-triazol-2-yl, 4- (hydroxymethyl)- lH-pyrazol- 1 -yl, 4-(hydroxymethyl)-2H- 1 ,2,3 -triazol-2-yl, 4- ((dimethylamino)methyl)-2H-l,2,3-triazol-2-yl, 4-methoxycarbonyl-2H-l,2,3-triazol-2-yl, 4-aminocarbonyl-2H-l,2,3-triazol-2-yl,l-methyl-lH-pyr
• R 6 is hydrogen or methyl
• Additional embodiments of the present invention include compounds of Formula (I) as herein defined, or an enantiomer, diastereomer, solvate, or a pharmaceutically acceptable salt form thereof, as exemplified in the listing in Table 1, below.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Pulmonology (AREA)
• Epidemiology (AREA)
• Physical Education & Sports Medicine (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (17)

Applications Claiming Priority (2)

Publications (1)

Family

ID=61628454

Family Applications (1)

Country Status (23)

Cited By (46)

Families Citing this family (20)

Citations (2)

Family Cites Families (69)

• 2017
  • 2017-12-19 TW TW106144535A patent/TWI795381B/zh active
  • 2017-12-20 MX MX2019007540A patent/MX392673B/es unknown
  • 2017-12-20 JP JP2019533465A patent/JP7138641B2/ja active Active
  • 2017-12-20 CN CN201780079706.3A patent/CN110214136A/zh active Pending
  • 2017-12-20 WO PCT/US2017/067516 patent/WO2018119036A1/en not_active Ceased
  • 2017-12-20 KR KR1020197021137A patent/KR102583317B1/ko active Active
  • 2017-12-20 EP EP17851862.7A patent/EP3558969B1/en active Active
  • 2017-12-20 PE PE2019001288A patent/PE20191755A1/es unknown
  • 2017-12-20 US US15/847,999 patent/US10954214B2/en active Active
  • 2017-12-20 ES ES17851862T patent/ES2992411T3/es active Active
  • 2017-12-20 UA UAA201908268A patent/UA127920C2/uk unknown
  • 2017-12-20 CA CA3048027A patent/CA3048027A1/en active Pending
  • 2017-12-20 TN TNP/2019/000192A patent/TN2019000192A1/en unknown
  • 2017-12-20 BR BR112019012355A patent/BR112019012355A2/pt not_active Application Discontinuation
  • 2017-12-20 MA MA047125A patent/MA47125A/fr unknown
  • 2017-12-20 EA EA201991503A patent/EA201991503A1/ru unknown
  • 2017-12-20 AU AU2017382185A patent/AU2017382185C1/en active Active
  • 2017-12-21 UY UY0001037537A patent/UY37537A/es not_active Application Discontinuation
  • 2017-12-21 AR ARP170103626A patent/AR110421A1/es not_active Application Discontinuation
• 2019
  • 2019-05-31 PH PH12019501212A patent/PH12019501212A1/en unknown
  • 2019-06-13 IL IL267343A patent/IL267343B2/en unknown
  • 2019-06-19 CL CL2019001709A patent/CL2019001709A1/es unknown
  • 2019-06-21 CO CONC2019/0006622A patent/CO2019006622A2/es unknown
  • 2019-06-21 MX MX2022005827A patent/MX2022005827A/es unknown
• 2020
  • 2020-11-25 US US17/104,081 patent/US12077521B2/en active Active
• 2022
  • 2022-02-28 AU AU2022201352A patent/AU2022201352A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (21)

Also Published As

Similar Documents

Legal Events